| Graphite | Not Annotated |  | Not Annotated | Graphite |
| Enmetazobactam | 314.32
C11H14N4O5S |  | A beta-lactamase inhibitor used to treat complicated urinary tract infections in combination with cefepime. | beta-Lactamase Inhibitors |
| Berdazimer | Not Available |  | A nitric oxide (NO)-releasing agent used to treat topical molluscum contagiosum. | Macromolecular Substances / Organosilicon Compounds / Polymers / Silicon Compounds |
| Lomifylline | 278.312
C13H18N4O3 |  | Not Annotated | Alkaloids / Drugs for Obstructive Airway Diseases / Heterocyclic Compounds, Fused-Ring / Purines / Purinones / Xanthine derivatives |
| Lotilaner | 596.75
C20H14Cl3F6N3O3S |  | An antiparasitic agent used to treat Demodex blepharitis. | Antiparasitic Agents / Ectoparasiticide / Ectoparasiticides, Incl. Scabicides / Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents / Sulfur Compounds |
| Flotufolastat F-18 | 1470.63
C63H99FN12O25Si |  | A radiopharmaceutical diagnostic agent used in PET imaging to visualize PSMA-positive lesions in men with prostate cancer with suspected metastasis or recurrence. | Diagnostic Radiopharmaceuticals / Fluorine Radioisotopes / Positron Emitting Activity / Radioactive Diagnostic Agent |
| Perfluorohexyloctane | 432.269
C14H17F13 |  | A drug used to treat dry eye disease. | Hydrocarbons, Fluorinated / Hydrocarbons, Halogenated / Ophthalmic Solutions / Ophthalmics / Ophthalmological and Otological Preparations / Ophthalmologicals |
| Pirtobrutinib | 479.436
C22H21F4N5O3 |  | A kinase inhibitor used to treat relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy. | Enzyme Inhibitors |
| Xenon Xe-129 | 128.9048
Xe |  | As a hyperpolarized contrast agent, it is indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation. | Contrast Media / Diagnostic Uses of Chemicals / Hyperpolarized Contrast Agent / Magnetic Resonance Imaging Contrast Media / Noble Gases / Xenon Isotopes |
| CVac | Not Annotated |  | Not Annotated | Not Annotated |
| Laurocapram | 281.484
C18H35NO |  | Not Annotated | Not Annotated |
| L-arginine | Not Annotated |  | Not Annotated | Arginine |
| Gadopiclenol | 970.1
C35H54GdN7O15 |  | A gadolinium-based contrast agent (GBCA) used with contrasted magnetic resonance imaging (MRI) to detect and visualize lesions and abnormal vascularity. | Contrast Media / Diagnostic Uses of Chemicals / Gadolinium-based Contrast Agent / Lanthanoid Series Elements / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / Paramagnetic Contrast Agent / Paramagnetic Contrast Media |
| Linzagolix | 508.42
C22H15F3N2O7S |  | A selective gonadotropin-releasing hormone (GnRH) receptor antagonist used for the symptomatic treatment of uterine fibroids. | Anti-Gonadotropin-Releasing Hormones |
| PBT-434 | 302.16
C12H13Cl2N3O2 |  | Not Annotated | Heterocyclic Compounds, Fused-Ring / Quinazolines |
| Zoledronate D,L-Lysine Monohydrate | 436.295
C11H26N4O10P2 |  | Not Annotated | Not Annotated |
| NBI-98782 | Not Annotated |  | Not Annotated | Not Annotated |
| Repotrectinib | 355.373
C18H18FN5O2 |  | A tyrosine kinase inhibitor used to treat locally active or metastatic non-small cell lung cancer | BCRP/ABCG2 Inhibitors / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C8 Inducers / Cytochrome P-450 CYP2C8 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Inhibitors / Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Kinase Inhibitor / MATE 2 Inhibitors / MATE inhibitors / OATP1B1/SLCO1B1 Inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / ROS1 tyrosine kinase inhibitors / Tyrosine Kinase Inhibitors / UGT1A1 Inhibitors |
| Lutetium Lu-177 vipivotide tetraxetan | 1216.074
C49H68LuN9O16 |  | A radioligand therapeutic agent used to treat prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in adults. | Radiopharmaceuticals / Theranostic Nanomedicine |
| Bortezomib D-mannitol | 530.39
C25H35BN4O8 |  | Not Annotated | Proteasome Inhibitors |
| Durlobactam | 277.25
C8H11N3O6S |  | A non-beta-lactam, beta-lactamase inhibitor used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. | Anti-Infective Agents / Enzyme Inhibitors |
| Belumosudil | 452.518
C26H24N6O2 |  | An oral inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK) used in the treatment of chronic graft-versus-host disease (GVHD). | Selective Immunosuppressants |
| Nirmatrelvir | 499.535
C23H32F3N5O4 |  | An oral protease inhibitor with emergency use authorization for the treatment of mild-to-moderate COVID-19. | Viral Protease Inhibitors |
| Deucravacitinib | 425.467
C20H22N8O3 |  | A TYK2 inhibitor being investigated as a treatment for psoriasis. | Selective Immunosuppressants |
| Serdexmethylphenidate | 499.52
C25H29N3O8 |  | A prodrug of the CNS stimulant dexmethylphenidate used as a first-line treatment for Attention Deficit Hyperactivity Disorder (ADHD). | Centrally Acting Sympathomimetics |
